|
Market Cap (16-May) $1,668,273,536 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 76.34 |
EPS 1.09 |
NEU released this announcement to the ASX on 27 October 2022, 9:35. The announcement is marked as price sensitive, and is 10 page(s) in length and 409.29kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.008% short sold according to ASIC data. It was ranked the 635th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Q3 2022 quarterly activity and cash flow report | 27 October 2022, 9:35 |
| Neuren receives US$10 million milestone payment | 20 October 2022, 9:30 |
| Investor presentation, 14 September 2022 | 14 September 2022, 12:52 |
| Rett Syndrome NDA accepted for Priority Review by FDA | 13 September 2022, 9:12 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 